Introduction: Targeted therapy is going to be the mainstay treatment of cancer diseases.In the recent years, the utilization of geftinib, erlotinib and bevacizuamb on metastatic or unresectable non-small cell lung cancer but usually showed slow response.Furthermore, combined targeted therapy with chemotherapy in some reports showed negative impacts on these patients.Therefore, for rapid response and improved survival, our aim is to design a combination of targeted therapy with chemotherapy in this study.During October, 2007 to April, 2009, we had preliminary study with enrollment of 7 patients with unresectable/metastatic non-small-cell-lung cancer in this study.There were 2 patients achieved CR, 3 PR, 2 SD.The median time to progression was 15 months.The response rate was 71.43%.The disease control rate was 100% for 9 months.And for patients responded to this treatment, the response was rapid.Patients and Methods: All patients should comply with the age older than 18 yrs, normal liver, renal function and ECOG below or equal to 2.The treatment protocol was sunitinib 25 mg day 1 to 5 and day 8 to 12, docetaxel 40mg on day 1, cisplatin 50 mg/m2 on day 1 with treatment interval of 14 days.Results: Formalapproval of this study by IRB was after April, 2009 and there were 6 patients enrolled in this study.There were 5 patients responded to this study with one PD.Two patients died during study but only one died of disease progression and the pathology of this patient was squamous cell carcinoma with clinical presentation of persistent hemorrhage.Another one died of intestinal perforation but not because of treatment but because of excess intake of beans with related intestinal obstruction.There were 1 CR, 3 PR and 1 SD.The response rate was 66.66% and the median time to progression was 15 months.Conclusion: In this study and its preiliminary study, the combination of sunitinib with chemotherapy would be an option for metastatic/unresectable non-small cell lung cancer patients.